share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  08/06 20:08
牛牛AI助理已提取核心訊息
On August 6, 2024, Clene Inc. announced the submission of new biomarker and clinical efficacy data for CNM-Au8 to the U.S. Food and Drug Administration (FDA) in support of its treatment for amyotrophic lateral sclerosis (ALS). The announcement was made through a press release, which is now filed as Exhibit 99.2 with the company's Current Report on Form 8-K. Additionally, Clene Inc. updated its corporate presentation on its investor relations website, which is furnished as Exhibit 99.1 in the same report. The company has indicated that future updates to the corporate presentation may be disseminated through its website without filing or furnishing a Current Report on Form 8-K to alert investors.
On August 6, 2024, Clene Inc. announced the submission of new biomarker and clinical efficacy data for CNM-Au8 to the U.S. Food and Drug Administration (FDA) in support of its treatment for amyotrophic lateral sclerosis (ALS). The announcement was made through a press release, which is now filed as Exhibit 99.2 with the company's Current Report on Form 8-K. Additionally, Clene Inc. updated its corporate presentation on its investor relations website, which is furnished as Exhibit 99.1 in the same report. The company has indicated that future updates to the corporate presentation may be disseminated through its website without filing or furnishing a Current Report on Form 8-K to alert investors.
2024年8月6日，Clene公司宣佈提交了CNm-Au8的新生物標誌物和臨床療效數據以支持其治療肌萎縮側索硬化症（ALS）的美國食品和藥物管理局（FDA）。該公告是通過新聞發佈會發佈的，現已作爲該公司在8-k表格中的附件99.2進行備案。此外，Clene公司在其投資者關係網站上更新了其企業介紹，該文件被作爲同一報告中的附件99.1進行發放。該公司表示，未來的企業介紹更新可能通過其網站傳播，而無需提交或分享8-k表格以提醒投資者。
2024年8月6日，Clene公司宣佈提交了CNm-Au8的新生物標誌物和臨床療效數據以支持其治療肌萎縮側索硬化症（ALS）的美國食品和藥物管理局（FDA）。該公告是通過新聞發佈會發佈的，現已作爲該公司在8-k表格中的附件99.2進行備案。此外，Clene公司在其投資者關係網站上更新了其企業介紹，該文件被作爲同一報告中的附件99.1進行發放。該公司表示，未來的企業介紹更新可能通過其網站傳播，而無需提交或分享8-k表格以提醒投資者。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。